Posts
- [eBook] Living with Duchenne Muscular Dystrophy (DMD): Tommy's Story
- [eBook] Living with Duchenne Muscular Dystrophy (DMD): Tommy's Story
- [eBook] Living with Spinal Muscular Atrophy: Sienna & Wesley's Stories
- [Patient Story] Living with Hereditary ATTR amyloidosis: Dennis' Story
- [Video] Gene Therapy Patient Case Management
- [Video] How a Specialty Pharmacy Can Make All the Difference for Patients
- [Video] Rare Disease Day: What's Your Why
- [Video] Rare Disease Patient Management
- [Video] The Value of a Specialty Pharmacy Partner for Manufacturers
- [Video] The Value of a Specialty Pharmacy Partner for Manufacturers
- 3 Opportunities for Patients with Rare & Complex Diseases in the Time of COVID-19
- 3 Proven Ways to Help Patients Manage the Costs of Specialty Medications for Rare Conditions
- 5 Services Providers Should Expect from a Specialty Pharmacy
- 5 Ways COVID-19 Impacts Immunocompromised & Rare Disease Patients
- 6 Facts About Alzheimer's Disease
- 6 Important Facts to Know About Hereditary Angioedema
- 6 Metrics to Track Specialty Pharmacy Patient Satisfaction
- 7 Common Characteristics of a Specialty Drug
- 7 Factors Payors Should Consider When Choosing a Specialty Pharmacy Partner
- 7 Facts About Rare Diseases to Raise Awareness on Rare Disease Day
- 7 Facts to Know About DMD on World Duchenne Awareness Day
- 7 Helpful Facts to Raise Awareness for Duchenne Muscular Dystrophy (DMD)
- 7 Ways to Support Caregivers During National Family Caregivers Month
- 8 Facts to Know About Mucopolysaccharidosis on MPS Awareness Day
- Adzynma (ADAMTS13, recombinant-krhn)
- Aldurazyme® (laronidase)
- Amondys 45™ (casimersen)
- Amvuttra® (vutrisiran)
- Arcalyst® (rilonacept)
- ATTRUBY™ (acoramidis)
- Austedo® (deutetrabenazine)
- Austedo® XR (deutetrabenazine)
- Berinert® [C1 esterase inhibitor (human)]
- Brineura® (cerliponase alfa)
- CASGEVY™ (exagamglogene autotemcel)
- Cerdelga® (eliglustat)
- Cerezyme® (imiglucerase)
- Choosing a Specialty Pharmacy to Support Duchenne Muscular Dystrophy
- Choosing a Specialty Pharmacy to Support ERT Therapies
- Choosing a Specialty Pharmacy to Support Hereditary Angioedema
- Choosing a Specialty Pharmacy to Support Hereditary ATTR Amyloidosis Patients
- Choosing a Specialty Pharmacy to Support Idiopathic Pulmonary Fibrosis Patients
- Choosing a Specialty Pharmacy to Support Mucopolysaccharidosis (MPS) Patients
- Choosing a Specialty Pharmacy to Support Patients with Recurrent Pericarditis
- Choosing a Specialty Pharmacy to Support Patients with X-linked hypophosphatemia
- Choosing a Specialty Pharmacy to Support Pompe Disease Patients
- Choosing a Specialty Pharmacy to Support Spinal Muscular Atrophy
- Choosing a Specialty Pharmacy to Support Spinal Muscular Atrophy
- Choosing a Specialty Pharmacy to Support Tardive Dyskinesia Patients
- Cinryze® [C1 esterase inhibitor (human)]
- Clinical & Operational Services to Consider When Selecting a Specialty Pharmacy Partner
- Communication & Collaboration Between a Pharmaceutical Manufacturer and Specialty Pharmacy
- COVID-19 Lengthens the Journey to Health Equity for Rare Disease Patients
- Crysvita® (burosumab-twza)
- Deflazacort
- Demystifying Four Common Pain Points for Patients Living with Rare Diseases
- Dietary Guidelines: Gaucher Disease Type 1 Patients Taking Miglustat
- Dojolvi® (triheptanoin)
- Elaprase® (idursulfase)
- Elelyso® (taliglucerase alfa)
- Elevidys™ (delandistrogene moxeparvovec-rokl)
- Elfabrio® (pegunigalsidase alfa-iwxj)
- Emflaza® (deflazacort)
- Esbriet® (pirfenidone)
- Evkeeza® (evinacumab-dgnb)
- Exondys 51® (eteplirsen)
- Fabrazyme® (agalsidase beta)
- Firazyr® (icatibant)
- Five Ways to Define and Redefine Rare Diseases
- From Diagnosis to Treatment: The Difficulties Rare Disease Patients Encounter
- FUROSCIX® (furosemide injection)
- Gene Therapy Guides Future Treatment for Rare Diseases
- Haegarda® [C1 esterase inhibitor subcutaneous (human)]
- Hemgenix® (etranacogene dezaparvovec-drlb)
- How to Manage the Administrative Burden of Prior Authorization
- How to Manage the Administrative Burden of Prior Authorization
- Icatibant Acetate
- Importance of Hand Hygiene in Healthcare: Handwashing Awareness Week
- Importance of the ACHC Distinction in Rare Diseases and Orphan Drugs for a Specialty Pharmacy Partner
- Ingrezza® (valbenazine)
- Intravenous Immunoglobulin (IVIG)
- Kalbitor® (ecallantide)
- Kanuma® (sebelipase alfa)
- LAMZEDE® (velmanase alfa-tycv)
- Leqvio® (inclisiran)
- Livdelzi® (seladelpar)
- Living with Duchenne Muscular Dystrophy: Tommy's Poem
- Lumizyme® (alglucosidase alfa)
- MACI® (autologous cultured chondrocytes on a porcine collagen membrane)
- Medical Benefits Billing for Specialty Therapies
- Mifepristone
- Miglustat
- MIPLYFFA™ (arimoclomol)
- Naglazyme® (galsulfase)
- Nexviazyme® (avalglucosidase alfa-ngpt)
- Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
- Ofev® (nintedanib)
- OLPRUVA® (sodium phenylbutyrate)
- Onpattro® (patisiran)
- Operational Challenges Payors Face with Rare Disease Limited Distribution Drugs
- Optimizing Patient Care Services with Rare Disease Limited Distribution Drugs
- Orsini Announcement: Orsini Specialty Pharmacy Chosen to Dispense YARGESA (miglustat)
- Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires
- Orsini Chosen as the Exclusive Specialty Pharmacy Provider for MIPLYFFA™ (arimoclomol), the First FDA-Approved Treatment for Niemann-Pick Disease Type C
- Orsini chosen by Ascendis to distribute treatment for rare endocrine disorder in the U.S.
- Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis
- Orsini Is Now a Specialty Pharmacy Provider for FUROSCIX® (furosemide injection), an Infused Diuretic for Congestive Heart Failure
- Orsini Launches ORBIT™ (Orsini Rare Business Intelligence Technology) to Enhance Rare Disease Patient Care
- Orsini Now a Specialty Pharmacy Provider for SAJAZIR™ (icatibant) Injection, to Treat Acute HAE Attacks
- Orsini Now Dispensing Livdelzi (seladelpar), for Treatment of Rare Liver Disease
- Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy
- Orsini Salutes Healthcare Quality Week
- Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
- Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
- Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
- Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
- Orsini Specialty Pharmacy Earns Rare Disease Pharmacy Center of Excellence Designation from URAC
- Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
- Orsini Specialty Pharmacy Now Dispensing VOWST™ (fecal microbiota spores, live – brpk)
- Orsini Specialty Pharmacy Offers Patients Access to Generic Treatment for Severe Homozygous Cystinuria
- Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
- Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
- Orsini Specialty Pharmacy Selected as a Limited Distribution Partner for AMVUTTRA™ (vutrisiran)
- Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
- Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
- Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK™
- Orsini Specialty Pharmacy Selected by Alnylam® Pharmaceuticals as Limited Distribution Partner for OXLUMO™
- Orsini Specialty Pharmacy Selected by Glaukos® Corporation as a Specialty Distribution Partner for Photrexa® and Photrexa® Viscous
- Orsini Specialty Pharmacy Selected by Glaukos® Corporation as a Specialty Distribution Partner for Photrexa® and Photrexa® Viscous
- Orsini Specialty Pharmacy Selected by Marinus Pharmaceuticals as the Exclusive Specialty Pharmacy Partner for ZTALMY®
- Orsini Specialty Pharmacy Selected by Provention Bio as a Limited Distribution Partner for TZIELD
- Orsini Specialty Pharmacy Selected by PTC Therapeutics as a Limited Distribution Partner for EMFLAZA® (deflazacort)
- Orsini Specialty Pharmacy Selected By Sanofi As A Limited Distribution Partner For Nexviazyme®
- Orsini Specialty Pharmacy Selected by Sarepta Therapeutics as a Limited Distribution Partner for AMONDYS 45 (casimersen)
- Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for Evkeeza™
- Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for Evkeeza™
- Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
- Orsini Specialty Pharmacy Selected to Dispense Aduhelm™ for the Treatment of Alzheimer's Disease
- Oxlumo® (lumasiran)
- Patients Share Their Journeys Living with Rare & Complex Diseases
- Payor Considerations When Evaluating a Specialty Pharmacy Partner
- PEDMARK® (sodium thiosulfate injection)
- Pharmaceutical Manufacturer & Payor Expectations When Partnering with a Specialty Pharmacy
- Photrexa® (riboflavin 5’-phosphate ophthalmic solution)
- Pirfenidone
- Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)
- Pradaxa® (dabigatran etexilate) oral pellets - pediatric
- Rare Disease Day: A Reminder of Our Immense Responsibility to Serve Patients and Families
- Rare Disease Day: In Loving Memory of Tommy
- Rare Disease Day: Raising Awareness for Patients Living with Rare Diseases
- Rare Disease Day: Raising Awareness for Patients Living with Rare Diseases
- Roctavian™ (valoctocogene roxaparvovec-rvox)
- Ruconest® [C1 esterase inhibitor (recombinant)]
- SAJAZIR™ (icatibant)
- Sinuva® (mometasone furoate)
- Six Reasons the Specialty Pharmacist Role is Increasingly Important
- Six Ways Orsini Ensures No Patient is Left Behind
- Six Ways the Right Specialty Pharmacy Partner Helps Improve Medication Adherence
- Six Ways to Help Patients Manage Rare Diseases
- Soliris® (eculizumab)
- Specialty Pharmacy Continuum: Gene Therapy a Hot Trend in Cold Chain
- Specialty Pharmacy Continuum: Specialty Pharmacies’ Role in Gene Therapy
- Tackling the Challenge of Health Literacy, One Word at a Time
- Takhzyro® (lanadelumab-flyo)
- The 3 Distribution Models to Choose for a Specialty Drug Launch
- The Burden of Prior Authorizations: How Specialty Pharmacies Can Help
- The Importance of Payor Credentialing When Selecting a Specialty Pharmacy Partner
- Three Reasons Why Newborn Screening Awareness Month is More Important than Ever
- Tiopronin
- Tzield® (teplizumab-mzwv)
- Ultomiris® (ravulizumab-cwvz)
- Veopoz™ (pozelimab-bbfg)
- Vigabatrin
- Viltepso® (viltolarsen)
- Vimizim® (elosulfase alfa)
- Vivitrol® (naltrexone)
- Vowst™ (fecal microbiota spores live-brpk)
- Vpriv® (velaglucerase alfa)
- Vyepti® (eptinezumab-jjmr)
- Vyndamax® (tafamidis)
- Vyndaqel® (tafamidis meglumine)
- Vyondys 53® (golodirsen)
- WAINUA™ (eplontersen)
- What is a Specialty Pharmacy?
- What Makes Orsini Special? Meet Our Specialty Pharmacists
- White Paper: Optimizing Patient Care in Rare Hematologic Conditions: Novel Therapies in Classical Hematology and the Role of Specialty Pharmacy in Driving Enhanced Outcomes
- Why You Need a Limited Distribution Network for Rare Disease Drugs
- Xenpozyme® (olipudase alfa-rpcp)
- Yargesa™ (miglustat)
- YORVIPATH® (palopegteriparatide)
- Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
- Zolgensma® (onasemnogene abeparvovec-xioi)
- Ztalmy® (ganaxolone)
Pages
- Accreditations
- Careers
- Contact an Account Executive
- Contact Us
- Find a Medication
- HAE Patient Connect Form
- HIPPA Privacy Policy
- Homepage
- Leadership
- NASP 2024 Orsini Presentations
- Our Story
- Patient Stories
- Amy's Journey with HAE Type III
- Annabelle's Journey with Mucopolysaccharidoses
- Austin and Max's Journeys with DMD
- Erin's Journey with XLH
- Joan's Journey with Tardive Dyskinesia
- Lisa's Journey with Hereditary Angioedema
- Nicholas' Journey with MPS Type II
- Robert's Journey with IPF
- Sienna and Wesley's Journeys with SMA
- Tommy's Journey with DMD In Loving Memory
- Prescribe a Therapy
- Privacy Notice
- Resources
- Sitemap
- Solutions
- Therapeutic Areas
- Who We Serve
- Zolgensma Referrals
Categories
- Blog Posts
- Drug
- Acid Sphingomyelinase Deficiency (ASMD)
- Alcohol Dependence
- Alpha-mannosidosis
- Aromatic L-amino acid decarboxylase (AADC) deficiency
- Aromatic L-amino acid decarboxylase (AADC) deficiency - Cell and Gene Therapy
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Bipolar Disorder
- Cartilage Defect Repair
- CD55-deficient protein-losing enteropathy (CHAPLE) Disease
- Ceroid Lipofuscinosis (C2LN)
- Congenital thrombotic thrombocytopenic purpura (c-TTP)
- Corneal Ectasia
- Cryopyrin-Associated Periodic Syndromes (CAPS)
- Cushing's Syndrome
- Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder
- Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
- Duchenne Muscular Dystrophy (DMD)
- Fabry disease
- Gaucher Type I Disease
- Heart failure
- Hemophilia A
- Hemophilia B
- Hereditary Angioedema (HAE)
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Home Nursing
- Homozygous Cystinuria
- Homozygous Familial Hypercholesterolemia (HoFH)
- Huntington’s Disease Chorea
- Hypoparathyroidism
- Idiopathic Pulmonary Fibrosis (IPF)
- Infantile Spasms
- Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Lysosomal Acid Lipase Deficiency (LAL-D)
- Major Depressive Disorder (MDD)
- Migraine
- Mucopolysaccharidosis Types I, II, VI, VII, IVA
- Nasal Polyps
- Niemann-Pick disease type C (NPC)
- Opioid Dependence
- Ototoxicity Associated With Cisplatin
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Polyneuropathy (PN)
- Pompe Disease
- Postpartum Depression
- Primary Biliary Cholangitis
- Primary Hyperlipidemia
- Primary Hyperoxaluria Type 1 (PH1)
- Primary Immune Deficiency
- Progressive Keratoconus
- Recurrent C. difficile Infection (rCDI)
- Recurrent Pericarditis (RP)
- Refractory Complex Partial Seizures
- Schizophrenia
- Sickle cell disease (SCD)
- Sickle cell disease (SCD) - Cell and Gene Therapy
- Spinal Muscular Atrophy (SMA)
- Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
- Tardive Dyskinesia (TD)
- Transfusion-dependent β-thalassemia (TDT)
- Transfusion-dependent β-thalassemia (TDT) - Cell and Gene Therapy
- Transthyretin-mediated amyloidosis - Cardiomyopathy (ATTR-CM)
- Transthyretin-mediated amyloidosis – Polyneuropathy (ATTR-PN)
- Tumor-induced Osteomalacia (TIO)
- Type 1 Diabetes (T1D)
- Urea Cycle Disorders (UCDs)
- Venous Thromboembolism (VTE)
- X-linked Hypophosphatemia (XLH)
- In the News
- Videos
- White Papers